Ferric carboxymaltose is under clinical development by Vifor Pharma Management and currently in Phase III for Congestive Heart Failure (Heart Failure). According to GlobalData, Phase III drugs for Congestive Heart Failure (Heart Failure) have a 53% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Ferric carboxymaltose’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ferric carboxymaltose overview
Ferric carboxymaltose (Ferinject, Injectafer, Renegy, Feryxa) is an iron replacement product. It is formulated as solution for intravenous route of administration. Ferric carboxymaltose is indicated for the treatment of iron deficiency when oral iron preparations are ineffective or cannot be used. It is under development for the treatment of restless legs syndrome, chemotherapy induced anemia, heart failure with iron deficiency and reduced ejection fraction.
It was also under development for the treatment of iron deficiency anemia.
Vifor Pharma Management overview
Vifor Pharma Management, a subsidiary of CSL Ltd, focuses on the discovery, development, and marketing of prescription medicines and non-prescription drugs specializes in areas such as iron deficiency, nephrology, and cardio-renal therapies. The company is headquartered in Glattbrugg, Switzerland.
For a complete picture of Ferric carboxymaltose’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
